Sugino, Keishi
Ono, Hirotaka
Watanabe, Natsumi
Ando, Masahiro
Tsuboi, Eiyasu
Homma, Sakae
Kishi, Kazuma
Article History
Received: 4 April 2021
Accepted: 24 June 2021
First Online: 10 July 2021
Declarations
:
: The study was approved by the Institutional Review Board of Tsuboi Hospital (No. Zizan 1–3). The Ethical Committees of Tsuboi Hospital waived the need for informed consent because of the retrospective clinical review.
: Not applicable.
: All authors contributed substantially to this work and are responsible for the consent of the manuscript. SH is a member of an endowed department sponsored by Teijin Pharma, Co., Ltd., Nippon Boehringer Ingelheim, Co., Ltd., Shionogi & Co., Ltd., and Chugai Pharmaceutical Co., Ltd. SH, KK, and KS have received lecture fees from Nippon Boehringer Ingelheim Co., Ltd. KK has received research funding from Nippon Boehringer Ingelheim Co., Ltd. The other authors have no financial relationships relevant to this article. All authors have no competing non-financial interests.